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 ABSTRACT
Kidney allocation from cadaveric donors must balance two main principles: medical utility and justice. 
The principle of medical benefit is gauged by maximizing efficiency in the use of organs and the principle 
of justice by its effectiveness, ensuring that all patients have a reasonable opportunity of transplantation. 
In this paper we present some metrics that, when applied to candidates for kidney transplantation, will 
help in the best judgment defining kidney allocation systems. Knowing the prevalence and incidence (per 
year, per million inhabitants) of kidney transplant, candidates demographic factors, such as: sex, age groups, 
and socioeconomic status; as well as clinical and immunological characteristics: blood group, Panel Reactive 
Antibody values, Body Mass Index, type of dialysis, cause of renal failure, and comorbidities; allows for an 
objective comparison of allocation programmes. The waiting time for transplantation should be measured 
as the median time between the start of dialysis and transplantation of wait -listed patients each year. By 
using the Cox regression analysis, with time on dialysis for transplantation as a dependent variable and 
clinical, socio -demographic factors as independent variables, we will shed light on which characteristics 
affect the access to transplantation.
Key -words: Kidney allocation; kidney transplantation; metrics; waiting time to transplantation.
 RESUMO
A distribuição de rins de dador cadáver deve equilibrar dois princípios fundamentais: a utilidade médica 
e a justiça. O princípio do benefício médico é aferido através da maximização da eficiência no uso dos 
órgãos, enquanto que o princípio da justiça visa garantir que todos os candidatos tenham uma oportuni-
dade razoável de transplante. Neste artigo, apresentamos algumas métricas que, quando aplicadas a can-
didatos a transplante de rim, ajudarão na melhor avaliação e definição de sistemas de distribuição de rins. 
Conhecer a prevalência e incidência (por ano e por milhão de habitantes) dos transplantes de rim, fatores 
Measuring kidney transplantation 
activity
Medindo a atividade de transplantação renal
Bruno A. Lima1, Miguel Mendes1, Helena Alves2
1 Biostatistics Office. Ermesinde, Portugal.
2 National Institute of Health, Dr Ricardo Jorge. Oporto, Portugal.
OPINION ARTICLE
Port J Nephrol Hypert 2014; 28(2): 171-176
Advance Access publication 6 June 2014
Received for publication: 27/04/2014
Accepted: 05/05/2014
Nefro - 28-2 - MIOLO.indd   171 01/07/2014   14:41:55
172    Port J Nephrol Hypert 2014; 28(2): 171-176
CMYKP
demográficos dos candidatos, tais como: sexo, faixa etária e nível socioeconómico; bem como as suas 
características clínicas e imunológicas: grupo sanguíneo, os valores do painel reativo de anticorpos, índice 
de massa corporal, tipo de diálise, a causa da insuficiência renal e co -morbilidades; permite uma compa-
ração objetiva de programas distribuição. O tempo de espera para o transplante deve ser medido como a 
mediana do tempo entre o início da diálise e o transplante dos doentes em lista de espera em cada ano. 
Através da análise de regressão de Cox, com o tempo em diálise para transplante como variável dependente 
e os fatores clínicos e sócio -demográficos como variáveis independentes, é possível identificar as caracter-
ísticas que afetam o acesso ao transplante.
Palavras -chave: Alocação do enxerto renal; métricas; tempo de espera para transplante; transplantação renal.
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 INTRODUCTION
The survival of renal transplanted patients, both 
at short - and long -term, is better than that of the 
patients on the waiting -list1. This survival benefit of 
transplanted patients when compared with dialyzed 
patients is independent of age and the presence of 
co -morbidities2 and persists even in patients over 
60 years of age.
In the European Union, approximately 360,000 
patients currently receive some form of renal replace-
ment therapy and of these, only one third live with 
a transplanted kidney3.
The transplanted patient’s risk of death compared 
with patients on the waiting -list varies with time. In 
the first weeks, the risk is higher (which is expected 
and is associated with the surgical procedure itself) 
and it reduces near the end of the first year of 
transplantation. This risk reduction in the long -term 
occurs in all subgroups of patients with regard to 
age, sex, ethnicity and cause of renal failure4.
Cardiovascular disease is very common among 
patients waiting for a kidney transplant and the risk 
of the disease increases during the waiting time5.
Dialysis favours the development of cardiovascular 
disease, osteoarthritis, anaemia and other diseases 
over time. Time on dialysis has proved to have a 
negative impact on the outcome of the transplant. 
Furthermore, transplantation is capable of correcting 
cardiovascular disease attributed to dialysis6. The pro-
tective effect from cerebrovascular events attributed 
to the transplant when compared with dialysis is even 
more evident when compared with return to dialysis 
after loss of the organ. There is evidence of increased 
risk of morbidity and mortality after graft loss7.
In this paper, we sought to identify factors that 
affect access to kidney transplantation and describe 
the best metrics that can characterize these factors.
 KIDNEY ALLOCATION
Kidney allocation on the basis of human leukocyte 
antigens (HLA) compatibility is a controversial topic. 
On one hand, this type of system is less equitable 
for patients in the access to transplantation but, on 
the other, it ensures better results for the outcome 
of the transplant8.
Human leukocyte antigens compatibility between 
donor and recipient has a major impact on recipients’ 
sensitization, which can be problematic if they need 
to be re -transplanted9.
There are socio -demographic and clinical factors 
associated with waiting times for deceased donor 
kidney transplantation, such as age, blood group or 
sensitization against HLA. The identification of these 
factors allows us to estimate waiting times for trans-
plant candidates, and so, better advise patients of 
the merits of living donation, especially those who 
may have longer waiting times10.
A kidney allocation programme must take into 
account factors related to the utility of transplantation: 
optimal HLA match for patients in whom it is most 
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relevant (children and youth); prioritization of children; 
minimization of ischaemia times and correlation of life 
expectancy of the graft with the recipient’s life expec-
tancy (similar ages). Also factors related to justice, 
such as: reduction of waiting times, greater equity of 
access for patients regardless of their ethnicity, blood 
group, HLA homozygosity and geographic location11.
The United Network of Organ Transplantation 
(UNOS) is a private non -profit organization in the 
USA responsible for coordinating and controlling the 
procedures for organ allocation. This organization 
considers that the distribution must be made in order 
to balance the principles of medical utility and justice. 
The value of medical benefit is guaranteed by maxi-
mizing efficiency in the use of organs, and the value 
of justice is guaranteed by ensuring that all patients 
have a reasonable opportunity to be transplanted12; 
nevertheless, kidney allocation system by UNOS is 
mostly based on time on dialysis.
As in the UNOS kidney allocation system, in many 
other countries, Portugal included13, distribution of 
organs is mainly based on the candidates’ time on 
dialysis. Often this method of distribution does not 
take into account both the expected lifespan of 
patients (whether transplanted or remaining on dialy-
sis), and the quality of the organs to distribute14.
A transparent policy based on efficiency criteria 
means that the organs would be transplanted into 
patients who would derive a greater benefit from 
them. Criteria of justice in access to transplantation 
conflict with the efficiency criteria. In the United King-
dom, in 2006, a revision of the laws governing organ 
allocation gave higher priority to candidates with 
longer waiting times and younger candidates, to the 
detriment of HLA compatibility criteria15. The English 
kidney allocation system is a points -system based 
on time on dialysis, HLA compatibility, age difference 
between donor and recipient and geographical prox-
imity in an attempt to allocate organs in a fair way 
reducing the weight of HLA compatibility and increas-
ing the importance of time on dialysis16. Eurotrans-
plant (ET), an international organization located in 
Leiden, in the Netherlands, and founded in 1967 by 
Prof. J. von Rood, is the largest organization of shar-
ing in Europe with seven member countries: Austria, 
Croatia, Germany, Luxembourg, Slovenia, the Neth-
erlands and Belgium17. The ET organ allocation system 
is based on 5 pillars: objectivity, transparency, clinical 
priority, compatibility and balance between countries. 
Its scoring system for organ distribution also takes 
into account  the candidate’s time on dialysis.
 TRANSPLANT OUTCOME
Several factors can influence kidney transplant 
outcome, for example: HLA compatibility, ischaemia 
time, duration of dialysis and the ages of donor and 
recipient11.
If the candidate with the highest probability of find-
ing a donor with a high number of HLA compatibilities 
must wait for that donor; those candidates for which 
the probability of finding a donor with few HLA com-
patibilities is very low (rare HLA) should be transplanted 
independently of the number of HLA mismatches18.
When compared to non -O candidates, ABO blood 
type O candidates wait longer for transplantation 
and more often are removed from the waiting list 
before transplantation. The use of pairs with blood 
type O donors and non -O recipients in a donor 
exchange programme, as well as a transplant pro-
gramme of ABO incompatible patients (organ trans-
plantation of A2 donors with low titers of anti -A 
recipients) certainly enhance the chances of these 
blood type O transplant candidates19.
The advantages of transplant outcome as far as 
reducing waiting times for transplantation should be 
actively sought. Programmes, such as the Eurotrans-
plant Senior Program, can be replicated in other coun-
tries and eventually extended to any and all candidates 
of 60 years of age facilitating a reduction in their 
waiting time20. Transplant candidates who start dialy-
sis in advanced age (> 65 years) are less likely to be 
transplanted16. About half of transplant candidates 
over 60 years of age quite likely die while waiting for 
a kidney transplant from a deceased donor21.
According to UNOS, Expanded Criteria Donors (ECD) 
are defined as donors older than 60 or older than 
50 years with at least two of the following criteria: 
creatinine > 1.5 mg/dl, history of hypertension or stroke 
as cause of death. Transplant candidates deemed 
‘extra risk’ are defined as being older than 60 or 
older than 50 with at least one of the following: 
coronary artery disease, peripheral arterial disease, 
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or diabetes20. Prolonged waiting time for a transplant 
in older patients negatively affects both patient sur-
vival as well as the graft itself. This problem can only 
be circumvented by requisition of living donors or 
with the use of ECD to reduce waiting times22.
Transplant recipients of an ECD have an increased 
risk of organ rejection compared to recipients of opti-
mal donors, however, the former still have a survival 
benefit compared with patients on dialysis23. This 
benefit of transplantation with ECD is directly propor-
tional to the increase in waiting time on dialysis24.
At risk transplant candidates have a very poor 
prognosis while awaiting an organ from a standard 
donor which is further worsened by increased dura-
tion of dialysis; meanwhile, the healthiest candidates 
may benefit from waiting longer for a standard donor 
instead of being transplanted with an ECD6.
It also stands to reason that post -circulatory death 
donors can be an appropriate and valuable contribu-
tion to increase the number of organs available for 
transplantation. The use of these donors for transplan-
tation translates into augmented opportunities for 
transplant candidates and reduction of waiting times25.
 HLA
The anti -HLA antibodies are mainly developed in 
patients undergoing blood transfusions, pregnancies 
or previous transplants. Patients with high levels of 
anti -HLA antibodies (hypersensitised) have their 
transplantation rates drastically reduced due to the 
immunological barrier of an increased risk of rejec-
tion26. Hypersensitized patients are fated to spend 
long periods of time on dialysis27 which in itself is 
a risk factor for patient and graft survival.
Panel reactive antibody (PRA) is defined as the 
percentage of an HLA antigen panel that reacts with 
the serum of the patient and may reflect the percent-
age of donors expected to react with patient sera28. 
This positive crossmatch probability can also be rep-
resented by the calculated PRA (cPRA) which is based 
on HLA antigens to which the patient is sensitized29. 
The PRA or the cPRA are the only immunity parameters 
that give prospective information about the possible 
response of a patient to an organ transplant.
Hypersensitised patients have two major draw-
backs: 1) Lower probability of finding a donor with 
a negative crossmatch and, therefore, tendency 
toward longer waiting time for a transplant, and 2) 
When transplanted, even with a negative crossmatch, 
higher risk of rejection episodes and graft lost30.
The options of renal transplant candidates sensi-
tised to a large number of HLA antigens are limited. 
The Australian experience shows that the distribution 
of living kidney donors on the basis of acceptable 
mismatches is an effective way to identify donors for 
some hypersensitised candidates within a relatively 
short space of time31. The concept of acceptable mis-
matches (AMM’s) assumes that antibody recognition 
of epitopes in HLA molecules occurs in certain areas 
of the HLA epitopes and that some of these are similar 
in different HLAs. The HLA Matchmaker algorithm vali-
dated by Eurotransplant uses the functional epitopes 
on areas of molecules of class I and II HLA32.
The anti -HLA antibodies can be identified by micro-
lymphocytotoxicity – complement dependent cyto-
toxicity (CDC), enzyme -linked immunosorbent assay 
(ELISA), Luminex, and methods for flow cytometry 
using a panel of known antigens, beads or HLA class 
I and II cells28.
With the development of laboratory and diagnostic 
techniques to determine the immune humoral 
response, it is possible to identify which anti -HLA 
antibody is injurious to the patient, thereby increasing 
the likelihood of success of a future transplant33. 
Although very sensitive solid phase tests have been 
available and in use for several years, their impact 
on the prediction of successful transplantation is con-
troversial, particularly when it is necessary to identify 
right cut -off values  for the most sensitive tests, such 
as the positivity of the single antigen test or in the 
definition of unacceptable anti -HLA antibodies33.
 METHODS
The population in study consists of patients that 
have been or still were present on the kidney trans-
plant waiting list. Data must be collected from several 
sources that manage these patients, i.e., nephrology 
clinics, haemodialysis facilities, histocompatibility 
laboratories and transplantation centres (Fig. 1). 
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Immunological data: presence of anti -HLA antibodies, 
ABO blood type, maximum percentage of PRA; clini-
cal and biological data: presence of comorbidities, 
body mass index, date of first RRT, date of registra-
tion on the waiting list for registered patients and 
date of transplantation for transplanted patients, 
dialysis modality and serum albumin; social and 
demographic data: age, gender, the distance between 
the patient’s residence and the transplantation centre 
calculated in kilometres, ethnicity, income and edu-
cation; these are some examples of the data that 
must be collected and analysed.
Figure 1
Data origin and flow of kidney transplant candidates
Data
compilation
Histocompatibility laboratories
Nephrology clinics
Transplantation
units
Hemodialysis
centres
Here we have described some statistics that should 
be used routinely in order to form a systematic 
picture of end -stage renal disease (ESRD) patients.
Incidence and prevalence of Renal Replacement 
Therapy (RRT) are two of the most common metrics 
used to characterize a population of ESRD patients. 
The unadjusted RRT incidence per million age -related 
population (p.m.a.r.p) is defined as the number of 
new patients on RRT in a year per age group (e.g. 
≥ 65 years of age) divided by the mid -year general 
population in that age group. The unadjusted preva-
lence of RRT p.m.a.r.p. is defined as the number of 
patients receiving RRT by or on the thirty -first of 
December of each year, per age group, divided by 
the mid -year general population in that age group.
For instance, point prevalence counts (candidates 
alive on the waiting list for kidney transplant by or on 
December thirty -first of each year) and new candidate 
counts by year. Organ waiting list numbers of all active 
patients compared on December thirty -first of each year 
will allow us to analyse efficiency of the policies applied 
to the management of waiting lists. Time on dialysis 
applies to the time that transplant recipients were on 
dialysis until transplantation and median waiting time 
to transplantation can be defined as the time on dialysis 
did it take before 50% of the waiting list patients in 
a given year received a transplant13,34.
The number of performed transplants per million 
population (p.m.p.) must be examined for each year 
combining different age groups. The number of per-
formed transplants p.m.p. per year is defined as the 
number of transplants performed in a year divided 
by the mid -year general population. Statistics on 
potential donor numbers, effective donor numbers, 
referral patterns by month, cause of death, type of 
donor, donor age, reason for denial of donation, 
mean organ yield per donor, percentage of effective 
donors per organ, number of transplants per organ, 
number of organ transplanted per million inhabitants 
can explain variations on organ waiting lists.
Survival rates calculated with life tables and actu-
arial methods and curves compared with Mantel-
-Hanzel test will allow us to calculate patients’ and 
graft survival including death with a functioning graft, 
as well as graft loss; this data will enable us to 
compare existing kidney allocation programmes and 
their merits. Other factors that can influence trans-
plant outcome can and must be identified.
A Cox proportional hazards regression, left-
-truncated for time since start of dialysis, can be 
used to assess time to kidney transplantation, with 
either a living or cadaveric kidney donor. Using a 
Cox multivariate hazard regression model with a time-
-dependent covariate, access to kidney transplanta-
tion can be analysed and modifiable factors that 
influence access can be identified35.
 CONCLUSION
Kidney transplantation is the preferred treatment 
for many ESRD patients; however, the small number 
of organs for transplantation does not allow all 
patients to have access to this scarce resource. Pool-
ing of transplant data grouping pathologies leading 
to terminal renal disease will be valuable to clarify 
HLA matching role and adapt different allocation 
criteria and different transplant strategies to different 
patient groups.
Measuring kidney transplantation activity
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For this reason it is of utmost importance to define 
objective and systematic metrics with clinical utility 
that allow making informed decisions when health 
policies are established for the distribution of an organ.
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